69 Results for "

human VEGFR2

" in MedChemExpress (MCE) Product Catalog:
Products (69)

69 Results for "human VEGFR2" in MCE Product Catalog:

  • Targets Recommended:
4
4 Cited Publications
Cat. No.: HY-N0876
CAS No.: 464-74-4
Arenobufagin is a natural bufadienolide that can be extracted from toad venom. Arenobufagin can induce apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Arenobufagin has potent antineoplastic activity against HCC HepG2 cells as well as corresponding multidrug-resistant HepG2/ADM cells. Arenobufagin can inhibit VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N4185
CAS No.: 61153-77-3
Licoflavone A is an orally active PTP1B/VEGFR-2 inhibitor, with an IC50 of 54.5 μM against PTP1B, an IC50 of 14.36 μM and a Kd of 142.38 nM against human VEGFR-2. Licoflavone A blocks the PI3K/AKT and MEK/ERK signaling pathways. Licoflavone A induces G1 phase cell cycle arrest, apoptosis via the intrinsic mitochondrial pathway (apoptosis), and inhibits migration, invasion and epithelial-mesenchymal transition (EMT) of gastric cancer cells. Licoflavone A inhibits the proliferation of gastric cancer cells in vitro and in xenograft models. Licoflavone A reduces the expression levels of HIF-1α, GLUT1, LDHA, PKM2 and HK2 in hypoxic gastric cancer cells, decreases glucose uptake and suppresses glycolysis. Licoflavone A can be used in research related to gastric cancer, type 2 diabetes and obesity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108801A
CAS No.: 862111-32-8
Purity:  97.66%

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease Cancer

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108801
CAS No.: 862111-32-8
Synonyms: VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

Target:  

VEGFR

Aflibercept is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9920A
CAS No.: 947687-13-0

Target:  

VEGFR

Research Areas:  

Cancer

Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0819
CAS No.: 89412-79-3
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N4322
CAS No.: 130848-06-5
Decursinol angelate acts as a PKC activator and GDH inhibitor, with an IC50 of 1.432 μM against human GDH. Decursinol angelate activates PKC, downregulates PKCα and PKCβII isoforms, and exerts cytotoxic activity against cancer cells. Decursinol angelate binds to GDH and inhibits its enzymatic activity. Decursinol angelate inhibits VEGF-induced autophosphorylation of VEGFR2, downstream p42/44 ERK and JNK-MAPK signaling pathways, as well as the angiogenesis process. Decursinol angelate is applicable to research related to cancer and leukemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1663
CAS No.: 272121-15-0
Target:  

VEGFR

Research Areas:  

Others

ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P70552
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: KDR; Fetal Liver Kinase 1; Kinase Insert Domain Receptor; Vascular Endothelial Growth Factor Receptor 2 Variant; Vascular Endothelial Growth Factor Receptor 2; Tyrosine Kinase Growth Factor Receptor; VEGFR2; Receptor Protein-Tyrosine Kinase; FLK1; Fetal L
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-108713
CAS No.: 1044040-56-3
Purity:  98.13%
Synonyms: SHR1020
Target:  

VEGFR PDGFR Apoptosis

Research Areas:  

Cancer

Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .
loading...
    loading...
Cat. No.: HY-P99768
CAS No.: 2095504-49-5
Synonyms: TTAC-0001; Tanibirumab

Target:  

VEGFR

Research Areas:  

Cancer

Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
loading...
    loading...
Cat. No.: HY-19624
CAS No.: 300842-64-2
Synonyms: ACC-789; ZK202650
Target:  

VEGFR PDGFR

Research Areas:  

Cancer

NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.
loading...
    loading...
Cat. No.: HY-137967
CAS No.: 38482-81-4
Purity:  ≥98.0%
Synonyms: Genistein 7-O-glucuronide
Target:  

Drug Metabolite

Research Areas:  

Metabolic Disease

Genistein 7-β-D-Glucuronide (Genistein 7-O-glucuronide) is the primary phase II metabolite of Genistein (HY-14596) in human and rat hepatocytes. Genistein 7-β-D-Glucuronide undergoes distinct deconjugation in different functional assays. Genistein 7-β-D-Glucuronide is produced via hepatic microsomal glucuronidation and shows a mild age-related increase in intrinsic clearance in male F344 rats. Genistein 7-β-D-Glucuronide can be used for research on metabolism .
loading...
    loading...
Cat. No.: HY-P99830
CAS No.: 1227158-72-6
Synonyms: KH902
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC50 = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (Kd = 0.5 pM), VEGF-B (Kd = 8 pM), VEGF-C, and PlGF (Kd = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .
loading...
    loading...
Cat. No.: HY-148877
CAS No.: 908112-37-8
Purity:  98.86%
AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs) .
loading...
    loading...
Cat. No.: HY-P99516
CAS No.: 2250342-36-8
Synonyms: HLX-06

Target:  

VEGFR

Research Areas:  

Cancer

Vulinacimab (HLX-06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-13645
CAS No.: 1239269-51-2
Target:  

VEGFR c-Kit PDGFR

Research Areas:  

Cancer

Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib inhibits the activity of VEGFR-2, c-kit, PDGFR with IC50 values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway in human umbilical vein endothelial cells (HUVECs) .
loading...
    loading...
Cat. No.: HY-108713A
CAS No.: 1256377-67-9
Synonyms: SHR1020 malate
Target:  

VEGFR PDGFR Apoptosis

Research Areas:  

Cancer

Famitinib (SHR1020) malate, an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib malate induces cell apoptosis. Famitinib malate exerts powerful antitumor activity in human gastric cancer cells and xenografts, it can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-N6926
CAS No.: 1073897-80-9
1,3,5-Tricaffeoylquinic acid acts as an angiogenesis inhibitor and apoptosis inducer, and exhibits anti-HIV activity. 1,3,5-Tricaffeoylquinic acid inhibits the phosphorylation of VEGFR2, ERK, PI3K, Akt and mTOR in the angiogenesis signaling pathway. 1,3,5-Tricaffeoylquinic acid regulates apoptosis-related proteins, upregulates the levels of activated caspase-8, Bax, activated PARP and caspase-3/9, while downregulates the level of Bcl-2. 1,3,5-Tricaffeoylquinic acid inhibits tube formation and shows cytotoxicity against ovarian cancer cells. 1,3,5-Tricaffeoylquinic acid can be used in studies related to ovarian cancer .
loading...
    loading...
Cat. No.: HY-138164
CAS No.: 81760-46-5
Cafestol palmitate is an orally active diterpene ester. Cafestol palmitate can be isolated from raw coffee beans. Cafestol palmitate enhances the activity of Glutathione S-transferase. Cafestol palmitate downregulates the expression of Akt and VEGFR2. Cafestol palmitate can be used in the research of inflammatory diseases and cardiovascular diseases .
loading...
    loading...